Daihan Pharmaceutical Coltd Stock Current Liabilities
| 023910 Stock | KRW 25,600 50.00 0.20% |
Daihan Pharmaceutical CoLtd fundamentals help investors to digest information that contributes to Daihan Pharmaceutical's financial success or failures. It also enables traders to predict the movement of Daihan Stock. The fundamental analysis module provides a way to measure Daihan Pharmaceutical's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Daihan Pharmaceutical stock.
Daihan |
Daihan Pharmaceutical CoLtd Company Current Liabilities Analysis
Daihan Pharmaceutical's Current Liabilities is the company's short term debt. This usually includes obligations that are due within the next 12 months or within one fiscal year. Current liabilities are very important in analyzing a company's financial health as it requires the company to convert some of its current assets into cash.
Current Daihan Pharmaceutical Current Liabilities | 42.01 B |
Most of Daihan Pharmaceutical's fundamental indicators, such as Current Liabilities, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Daihan Pharmaceutical CoLtd is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Current liabilities appear on the company's balance sheet and include all short term debt accounts, accounts and notes payable, accrued liabilities as well as current payments due on the long-term loans. One of the most useful applications of Current Liabilities is the current ratio which is defined as current assets divided by its current liabilities. High current ratios mean that current assets are more than sufficient to pay off current liabilities.
| Competition |
In accordance with the recently published financial statements, Daihan Pharmaceutical CoLtd has a Current Liabilities of 42.01 B. This is much higher than that of the Healthcare sector and significantly higher than that of the Pharmaceuticals industry. The current liabilities for all Republic of Korea stocks is significantly lower than that of the firm.
Daihan Current Liabilities Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Daihan Pharmaceutical's direct or indirect competition against its Current Liabilities to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Daihan Pharmaceutical could also be used in its relative valuation, which is a method of valuing Daihan Pharmaceutical by comparing valuation metrics of similar companies.Daihan Pharmaceutical is currently under evaluation in current liabilities category among its peers.
Daihan Fundamentals
| Return On Equity | 12.49 | |||
| Return On Asset | 0.0677 | |||
| Profit Margin | 0.10 % | |||
| Operating Margin | 0.17 % | |||
| Current Valuation | 148.23 B | |||
| Shares Outstanding | 6 M | |||
| Shares Owned By Insiders | 34.84 % | |||
| Shares Owned By Institutions | 13.66 % | |||
| Price To Earning | 11.74 X | |||
| Price To Sales | 0.93 X | |||
| Revenue | 171.46 B | |||
| Gross Profit | 56.19 B | |||
| EBITDA | 39.72 B | |||
| Net Income | 22.67 B | |||
| Cash And Equivalents | 83.73 B | |||
| Total Debt | 14 B | |||
| Debt To Equity | 0.15 % | |||
| Current Ratio | 3.12 X | |||
| Cash Flow From Operations | 40.62 B | |||
| Target Price | 58000.0 | |||
| Beta | 0.53 | |||
| Market Capitalization | 182.1 B | |||
| Total Asset | 272.54 B | |||
| Retained Earnings | 67.17 B | |||
| Working Capital | 33.04 B | |||
| Current Asset | 75.05 B | |||
| Current Liabilities | 42.01 B | |||
| Z Score | 7.8 | |||
| Annual Yield | 0.01 % | |||
| Net Asset | 272.54 B |
About Daihan Pharmaceutical Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Daihan Pharmaceutical CoLtd's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Daihan Pharmaceutical using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Daihan Pharmaceutical CoLtd based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Pair Trading with Daihan Pharmaceutical
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Daihan Pharmaceutical position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Daihan Pharmaceutical will appreciate offsetting losses from the drop in the long position's value.Moving against Daihan Stock
| 0.79 | 102940 | Kolon Life Science | PairCorr |
| 0.66 | 106190 | High Tech Pharm | PairCorr |
| 0.58 | 027710 | FarmStory | PairCorr |
| 0.36 | 012860 | Mobase Electronics CoLtd | PairCorr |
| 0.36 | 101400 | N Citron | PairCorr |
The ability to find closely correlated positions to Daihan Pharmaceutical could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Daihan Pharmaceutical when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Daihan Pharmaceutical - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Daihan Pharmaceutical CoLtd to buy it.
The correlation of Daihan Pharmaceutical is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Daihan Pharmaceutical moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Daihan Pharmaceutical moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Daihan Pharmaceutical can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Other Information on Investing in Daihan Stock
Daihan Pharmaceutical financial ratios help investors to determine whether Daihan Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Daihan with respect to the benefits of owning Daihan Pharmaceutical security.